Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.

@article{Galligioni2006GemcitabineAA,
  title={Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.},
  author={Enzo Galligioni and Carmela Arcuri and Roberto Sorio and Claudia Griso},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2006},
  volume={17 Suppl 5},
  pages={v195-8}
}
BACKGROUND Most of the patients with advanced ovarian cancer will recur after first-line platinum-based chemotherapy and need additional treatment. Gemcitabine (G) and Anthracyclines are active in this setting and their combination has shown synergistic antiproliferative activity in vitro, due to different mechanisms of action and non-overlapping toxicities. PATIENTS AND METHODS In 2002 we began a phase II study with G 1000 mg/m(2) (day 1,8) combined to Epirubicin (E) 60 mg/m(2) (day 1… CONTINUE READING